Drug Type Monoclonal antibody |
Synonyms HFB 100204, HFB-1002 |
Target |
Mechanism CXCR5 antagonists(C-X-C motif chemokine receptor 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | - | 01 Apr 2022 | |
Hematologic Neoplasms | Preclinical | - | 01 Apr 2022 |